Estherline Thoby | Medicine and Health Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Estherline J. Thoby
Rutgers Robert Wood Johnson Medical School, United States

Estherline Thoby
Affiliation Rutgers Robert Wood Johnson Medical School
Country United States
Scopus ID 57201254799
Documents 4
Citations 26
h-index 2
Subject area Medicine and Health Sciences
Event Global Innovation Technologist Awards

The Innovative Research Award profile presents Estherline Thoby’s documented scholarly activity in medicine and health sciences, with particular attention to pediatric practice and neonatal hyperbilirubinemia. Her listed publication, “Pediatricians’ Practice Patterns on the Revised 2022 Neonatal Hyperbilirubinemia Guidelines,” addresses clinical practice in the context of updated guidance for neonatal jaundice. The profile summarizes the supplied bibliometric information and identifies the research themes relevant to academic recognition. The available information does not establish an award decision or independent assessment outcome.

Abstract

Estherline J. Thoby is associated with research in pediatric medicine and neonatal hyperbilirubinemia. Her listed 2026 publication examines pediatricians’ practice patterns concerning the revised 2022 neonatal hyperbilirubinemia guidelines. This topic is relevant to understanding how clinical recommendations are interpreted and applied in pediatric settings. The supplied Scopus profile reports four documents, 26 citations and an h-index of 2. These figures provide a limited bibliometric snapshot rather than a complete evaluation of clinical relevance, methodological quality or research contribution. [1]

Keywords

Estherline Thoby; neonatal hyperbilirubinemia; pediatric practice; clinical guidelines; neonatal jaundice; evidence-based medicine; pediatricians; medicine and health sciences; research impact.

Introduction

Neonatal hyperbilirubinemia is a common clinical concern involving elevated bilirubin levels in newborns. Clinical guidelines support decisions about risk assessment, monitoring and treatment. Examining pediatricians’ practice patterns can help describe the relationship between published recommendations and real-world clinical approaches. The 2022 revised guidance provides the context for the publication attributed to Thoby and co-authors. The available citation information identifies a relevant research topic, but detailed findings should be drawn from the full article rather than inferred from its title. [2]

Research Profile

The supplied institutional affiliation is Rutgers Robert Wood Johnson Medical School in the United States. The profile identifies medicine and health sciences as the subject area. The reported bibliometric indicators are four documents, 26 citations and an h-index of 2. These metrics describe indexed scholarly output and citation activity as supplied; they may change as databases are updated. The information provided does not independently verify employment dates, authorship contributions or the completeness of the publication record.

Research Contributions

The identified research topic concerns the implementation of revised neonatal hyperbilirubinemia guidance in pediatric practice. Research on practice patterns can help characterize clinicians’ familiarity with recommendations and identify areas for further education or investigation. However, specific conclusions about adherence, treatment choices or patient outcomes cannot be established from the citation metadata alone. Assessment of these contributions requires the full publication, including its methods, results and limitations.

Publications

The supplied publication record is:

  • Pediatricians’ Practice Patterns on the Revised 2022 Neonatal Hyperbilirubinemia Guidelines. Authors listed: E. J. Thoby, A. A. Lariviere, K. A. Briski and A. Petrova. Pediatric Reports, 2026. The supplied record reports zero citations for this individual article at the time of the provided snapshot.

A DOI and direct full-text URL were not supplied and are therefore not asserted here. The publication title and author details should be checked against the journal’s official record before formal bibliographic reuse.

Research Impact

The supplied Scopus figures indicate a modest indexed publication record with measurable citation activity. Citation counts and h-index can support comparisons when interpreted alongside career stage, specialty, authorship role and publication context. They do not independently measure clinical influence, originality or patient benefit. Because the identified 2026 article is reported with zero citations, its potential influence should be assessed over time and through substantive review of its findings.

Award Suitability

The Innovative Research Award profile for the Global Innovation Technologist Awards provides a framework for presenting the researcher’s subject area, publication activity and research interests. Relevant considerations for a formal award evaluation include:

  • Relevance and originality of the research question.
  • Methodological quality and transparency of reported findings.
  • Potential contribution to pediatric practice and evidence-based care.
  • Verified publication records and independently documented research outcomes.

These considerations are evaluation criteria, not confirmation that an award has been granted. A final determination requires the event’s official assessment process and supporting evidence.

Conclusion

Estherline Thoby’s listed work addresses a clinically relevant topic in neonatal and pediatric medicine. The available profile provides basic bibliometric information and a 2026 publication reference, while leaving the article’s detailed findings and broader clinical implications to be verified from primary sources. This page serves as a neutral academic recognition profile, not an independent validation of research quality or an announcement of award selection.

References

  1. Elsevier. (n.d.). Scopus author details: Author ID 57201254799. Scopus. Bibliometric figures reproduced from the information supplied for this profile.
    https://www.scopus.com/authid/detail.uri?authorId=57201254799
  2. Thoby, E. J., Lariviere, A. A., Briski, K. A., & Petrova, A. (2026). Pediatricians’ Practice Patterns on the Revised 2022 Neonatal Hyperbilirubinemia Guidelines. Pediatric Reports. Publication details are transcribed from the supplied citation; volume, issue, page range and DOI were not provided.
  3. Kemper, A. R., Newman, T. B., Slaughter, J. L., et al. (2022). Clinical practice guideline revision: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics, 150(3), e2022058859.
    https://doi.org/10.1542/peds.2022-058859
  4. World Health Organization. (n.d.). Newborn health. World Health Organization. General reference for newborn health context.
  5. Global Innovation Technologist Awards. (n.d.). Official award website.
    innovationtechnologist.com

Mehmet Kızılkaya | Medicine and Health Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Mehmet Kızılkaya
Trabzon Kanuni Training and Research Hospital, Turkey

Mehmet Kızılkaya
Affiliation Trabzon Kanuni Training and Research Hospital
Country Turkey
Google Scholar ID LoT5L1kAAAAJ
Documents 1
Citations 1
h-index 1
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards

Mehmet Kızılkaya is a researcher affiliated with Trabzon Kanuni Training and Research Hospital in Turkey, working within the broad field of Medicine and Health Sciences. The available publication record identifies a 2026 research contribution concerning prognostic indicators in older patients with prostate cancer undergoing definitive radiotherapy. The documented work examines myopenia, myosteatosis, and frailty as clinically relevant characteristics in this patient population. [1]

Abstract

This academic recognition profile presents the available research record associated with Mehmet Kızılkaya. The documented publication addresses the prognostic significance of myopenia, myosteatosis, and frailty among older patients with prostate cancer receiving definitive radiotherapy. These variables represent aspects of muscle quantity, muscle quality, and overall vulnerability that may contribute to the clinical characterization of older oncology patients. The publication appeared in Cancer Control in 2026 and lists Kızılkaya among its authors. [1]

Keywords

  • Prostate cancer
  • Radiotherapy
  • Myopenia
  • Frailty
  • Geriatric oncology

Introduction

Age-associated changes in muscle mass, muscle composition, and functional reserve are increasingly considered in the assessment of older adults with cancer. In prostate cancer, definitive radiotherapy is an established treatment approach, while patient-level characteristics can influence prognosis and treatment planning. The reported study focuses specifically on myopenia, myosteatosis, and frailty, providing a clinical research perspective on these factors in older patients receiving radiotherapy. [1]

Research Profile

The available bibliographic information records one research document and one citation, with an h-index of 1 in the supplied profile data. The documented publication is situated within Medicine and Health Sciences and concerns an interdisciplinary clinical question connecting oncology, radiotherapy, geriatric assessment, and body-composition-related prognostic factors. Because only a limited set of bibliometric information is available, broader measures of research productivity and longitudinal impact should be interpreted cautiously.

Research Contributions

Kızılkaya’s documented contribution is part of a multi-author investigation of prognostic characteristics in older patients with prostate cancer. The study’s focus on myopenia, myosteatosis, and frailty contributes to a research framework in which conventional cancer outcomes can be considered alongside patient-specific physical characteristics. The work also illustrates collaboration across clinical disciplines involved in cancer management and radiotherapy. [1]

Publications

Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy — RA Aksoy, T Koca, DA Çetmi, M Kızılkaya, and AF Korcum. Published in Cancer Control, volume 33, in 2026. The available record reports article identifier 10732748261446040 and one citation. [1]

Research Impact

The available citation record documents an early bibliometric impact for the reported publication. With one document and one citation in the supplied data, quantitative indicators remain limited and should not be interpreted as a comprehensive measure of scholarly influence. The clinical relevance of the research can instead be understood through its focus on prognostic assessment in an older prostate-cancer population and its integration of muscle-related and frailty-related characteristics. [1]

Award Suitability

For the Innovative Research Award associated with the Global Innovation Technologist Awards, the documented research provides identifiable evidence of participation in contemporary clinical research involving prostate cancer, definitive radiotherapy, and prognostic characteristics of older patients. Relevant considerations include the specificity of the research question, its multidisciplinary clinical context, and the publication record available for verification. A complete award assessment would require the relevant official profile identifiers and any additional documented research outputs supplied for evaluation.

Conclusion

The available record identifies Mehmet Kızılkaya as a contributor to research examining myopenia, myosteatosis, and frailty in older patients with prostate cancer undergoing definitive radiotherapy. The publication establishes a clear connection with Medicine and Health Sciences and provides a documented basis for recognizing research activity in clinical oncology. Additional publications, identifiers, citations, and longitudinal metrics would allow a more comprehensive assessment of the research profile.

References

  1. Aksoy, R. A., Koca, T., Çetmi, D. A., Kızılkaya, M., & Korcum, A. F. (2026). Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy.
    https://journals.sagepub.com/doi/full/10.1177/10732748261446040
  2. Cancer Control. (2026). Bibliographic record for the reported prostate cancer radiotherapy research article.
  3. Google Scholar. (2026). Citation record associated with the reported publication.
  4. Global Innovation Technologist Awards. (n.d.). Official awards website.
    innovationtechnologist.com
  5. SAGE Journals. (n.d.). Cancer Control: Journal information and publication platform.